Aesthetic Medical International Holdings Group (PAIYY) AI Stock Analysis

• Market Cap: $12.65M
• Dividend Yield: N/A
• Average Volume (3M): 1.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1,286
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 48,687,584
• 10 Day Avg. Volume: 1,205
• 30 Day Avg. Volume: 1,949
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $0.50
• Price Target Upside: 92.31% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: $0.50 ▲(92.31% Upside)

The overall stock score is primarily influenced by financial performance, which shows improvement in revenue and cash flow but continues to struggle with profitability and high leverage. Technical analysis suggests some short-term bullish momentum, but valuation concerns due to lack of earnings and dividends weigh heavily on the score.

Aesthetic Medical International Holdings Group Business Overview & Revenue Model

Company Description

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China and Singapore. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and radiofrequency treatments. It also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. The company was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.

How the Company Makes Money

Aesthetic Medical International Holdings Group generates revenue primarily through its aesthetic medical services, which include both surgical and non-surgical procedures. These services are offered across various treatment centers strategically located to capture a broad customer base. The company also benefits from selling skincare and beauty products as part of their service offerings. Additionally, PAIYY may engage in partnerships with medical technology firms to enhance their service delivery, potentially creating additional revenue streams through collaborative service enhancements or innovative product offerings.

Aesthetic Medical International Holdings Group Financial Statement Overview

Summary

Aesthetic Medical International Holdings Group shows signs of improvement in cash flow management and a slight revenue increase. However, the company continues to face significant challenges with profitability and leverage. The balance sheet remains highly leveraged, posing financial risks, while the income statement reveals ongoing operational inefficiencies. Although there is progress, the company needs to focus on reducing debt and improving margins to enhance its financial stability.

Income Statement

The company has shown a slight revenue growth of 1.86% in the latest year, but its net profit margin remains negative due to consistent net losses. The gross profit margin has decreased from 53.06% in 2022 to 47.19% in 2023, indicating reduced efficiency in managing production costs. EBIT margin remains negative, highlighting ongoing operational challenges. Despite a positive EBITDA in 2023, the overall profitability remains weak.

Balance Sheet

The debt-to-equity ratio is concerning given the high level of total debt relative to a low equity base. However, there has been a positive shift with equity turning positive in 2023. The equity ratio is low at 8.72%, indicating high leverage and potential risks. Return on equity, while still negative, shows a significant improvement compared to prior years due to reduced net losses.

Cash Flow

Free cash flow has improved significantly from a negative value in 2022 to a positive value in 2023, indicating better cash management. The operating cash flow to net income ratio is strong, suggesting that the company generates cash effectively relative to its reported losses. However, there is potential risk associated with the sustainability of these cash flow improvements given the historical volatility.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	682.59M	670.09M	645.59M	901.57M
Gross Profit	322.05M	355.59M	269.50M	544.78M
EBITDA	25.31M	-11.05M	-554.95M	-123.90M
Net Income	-37.43M	-76.25M	-586.62M	-235.48M
Balance Sheet
Total Assets	560.66M	546.37M	576.94M	1.04B
Cash, Cash Equivalents and Short-Term Investments	62.34M	12.16M	39.29M	44.38M
Total Debt	244.55M	393.10M	405.91M	460.79M
Total Liabilities	527.03M	672.25M	763.36M	612.35M
Stockholders Equity	48.89M	-113.66M	-156.67M	390.90M
Cash Flow
Free Cash Flow	18.83M	-76.80M	17.65M	-46.01M
Operating Cash Flow	74.29M	-75.13M	51.09M	-843.00K
Investing Cash Flow	-52.25M	3.11M	-11.53M	-127.37M
Financing Cash Flow	29.06M	45.55M	-45.23M	17.70M

Aesthetic Medical International Holdings Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAIYY, the sentiment is Positive. The current price of 0.26 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.20, and above the 200-day MA of 0.24, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.95 is Neutral, neither overbought nor oversold. The STOCH value of 50.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PAIYY.

Aesthetic Medical International Holdings Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%
PAIYY	47 Neutral	$12.65M	―	-76.57%	―	―	―
PSTV	45 Neutral	$48.09M	―	249.03%	―	-14.43%	16.04%
CCM	40 Underperform	$22.14M	―	14.03%	―	-29.82%	-2.57%
ERNA	―	$12.51M	―	-2264.31%	―	―	―
SNSE	40 Underperform	$9.65M	―	-64.18%	―	―	3.99%
GOVX	34 Underperform	$17.22M	―	-9690.24%	―	1943.07%	80.97%